Table 1 Demographic and clinical characteristics and treatment modalities in patients with Brucella arhtritis
From: Diagnostic role of inflammatory markers in pediatric Brucella arthritis
Clinical features | Mean ± SD, median range or number (%) (n:64) |
|---|---|
Mean age (month) | 92.3 ± 41.2 |
Gender | |
Male | 34 (53.1) |
Female | 30 (46.9) |
Duration of hospitalization (day) | 6 (2–76) |
Symptoms and clinical findings | |
Arthralgia | 64 (100) |
Joint pain | 61 (95.3) |
Fever | 55 (85.9) |
Myalgia | 49 (76.6) |
Anorexia | 46 (71.9) |
Weakness | 40 (62.5) |
Shivering | 39 (60.9) |
Restriction of movement | 36 (56.2) |
Diaphoresis | 33 (51.6) |
Swelling | 22 (34.3) |
Increase temperature on joint | 22 (34.3) |
Joint redness | 22 (34.3) |
Headache | 20 (31.3) |
Abdominal pain | 14 (21.9) |
Joint effusion | 13 (20.3) |
Chest pain | 11 (17.2) |
Neck pain | 2 (3.1) |
Joint involvement | |
Ankle | 34 (53.1) |
Knee | 30 (46.9) |
Laboratory findings | |
Erythrocyte sedimentation rate (mm/h) | 40.9 ± 20.4 |
C-reactive protein (mg/L) | 28.1 ± 22.4 |
Brucella hemagglutination test | |
160 | 10 (15.8) |
320 | 25 (39.1) |
≥640 | 29 (45.3) |
Positive culture | |
Blood | 4 (6.3) |
Joint puncture | 4 (6.3) |
Blood + Joint puncture | 5 (7.9) |
Treatment | |
Rifampicin + Tetracycline + Streptomycin | 13 (20.3) |
Rifampicin + Tetracycline + Gentamicin | 14 (21.8) |
Rifampicin + TMP-SMX + Gentamicin | 37 (57.8) |